In addition, we report here the identification of ECM proteins not previously associated with tumor progression (fibrillin 1, Vwa5a, hemicentin) and it would be interesting to evaluate whether they play a functional role in the angiogenic switch and support tumor progression since, if they do, they could serve as potential anti-angiogenic or anti-tumor therapeutic targets. This evidence concerns the gene FBN1 and neoplasm.